Granules India share price will remain in focus on November 3 following the company posted better earnings for the quarter ended September 2026 (Q2FY17). The company had reported a 39.2% year-on-year increase in net profit to Rs 182 crore in Q2, compared with Rs 131 crore a year ago. Revenue of the company rose 20.3% to Rs 1,560 crore from Rs 1,297 crore, while EBITDA increased 21.3% to Rs 337.4 crore from Rs 278.1 crore.

EBITDA margin improved to 21.6% from 21.4% in the year-ago period. Catch all the market action on our live blog The USFDA was conducted a current Good Manufacturing Practice inspection from October 19 to October 30, 2026, at finished dosage facility at Gagillapur, Hyderabad. and concluded with the issuance of a Form FDA 483 containing eleven observations. In the previous trading session, the share closed at Rs 819.55, down Rs 20.00, or 2.38 percent.

The share touched a 52-week high of Rs 922.10 and a 52-week low of Rs 520.05 on 15 September, 2026 and 02 March, 2026, respectively. Currently, the stock is trading 11.12 percent below its 52-week high and 57.59 percent above its 52-week low. The market capitalisation of the company stands at Rs 20,308.20 crore.